Mirtazapina Farmoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Farmoz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and may improve sleep, appetite, and overall mood.

GNH USA supplies Mirtazapina Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global network ensures consistent quality, regulatory compliance, and timely delivery to meet the needs of healthcare providers across multiple regions.

Mirtazapine is indicated for depressive disorders and works within the serotonergic and noradrenergic pathways to improve mood. - Major depressive disorder: reduces depressive symptoms and improves overall functioning in adults. - Depressive episodes with melancholic features: alleviates severe mood disturbances and associated sleep loss. - Adjunctive therapy for bipolar depression: used under specialist supervision to manage depressive phases.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Sedation or drowsiness. - Increased appetite leading to weight gain. - Dry mouth. - Constipation. - Dizziness. - Peripheral edema.

Serious or Rare Side Effects: - Agranulocytosis or neutropenia. - Severe hypersensitivity reactions, including Stevens‑Johnson syndrome. - Suicidal thoughts or worsening depression. - Seizures. - Hepatic dysfunction.

When prescribing mirtazapine, clinicians should consider several safety measures. - Monitor for worsening depression: assess suicidal ideation regularly. - Assess hepatic function: adjust dose in severe impairment. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper under medical supervision. - Store at ambient temperature: keep in original pack, protect from moisture.

Mirtazapine interacts with several drug classes; awareness helps prevent adverse outcomes. Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; ensure a 14‑day washout. - Other serotonergic agents (SSRIs, SNRIs, tramadol): potential serotonin syndrome. - CNS depressants (alcohol, benzodiazepines): enhanced sedation and respiratory depression. Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure lowering effect. - Anticholinergic drugs: increased anticholinergic burden. - Carbamazepine: may reduce mirtazapine plasma levels.